The Effect Size Is 0.81. The Number That Decides the Business Is 6.4 Hours.
Effect size 0.81 settles the efficacy question. The number that decides the business is 6.4 hours of supervised monitoring per dose.
By subject
Lilly Can Sue the Sellers. It Can Only Ask the Payment Networks.
Six suits against small peptide sellers is not a strategy for a market spanning a hundred countries. It is a demonstration attached to an appeal.
In Japan, Expanding a Label Is What Triggers the Price Cut
Dupixent, Nucala and Vyvdura were all cut after adding an indication. In Japan the trigger for a price cut is the drug reaching more patients.
Black Diamond Bought a Licence Instead of a Ruling, and Six Patents Stay Untested
These were not patents on a drug. They were patents on the methods used to find one, and Black Diamond has agreed to pay rather than test them.
Australia Cannot Settle Its Device Price Fight While the Service Sits Inside the Price
Both sides are fighting over a number nobody can produce. The evaluation went underneath them and named the reason: the service is inside the price.
Oman Is Offering Drug Manufacturers the One Thing Government Procurement Normally Destroys
Committing 30% of a health ministry’s requirement at agreed prices means deciding not to buy the cheapest product. Somebody is paying for that.
No Product Is Approved for Hernia Prevention. BD Is Spending Five Years to Change That.
BD is not testing a product against a competitor. It is testing whether an indication can be brought into existence, with no label, code or precedent.
Korea Cleared Two Diagnostics on One Day, and Both Remove a Specialist
Nobody gained insurance access. Designation is the gate before the negotiation. The real story is that both lead technologies remove a specialist.
FastWave’s Pivotal Trial Cannot Measure the Thing FastWave Is Selling
Everything FastWave sells is comparative. The word its chief executive used is clearance, and clearance means substantially equivalent.
The MHRA Authorised Two Obesity Drugs in Two Days. Neither Is on the NHS.
Two MHRA authorisations in two days. One drug is too common to fund, the other too rare to prioritise. Neither is on the NHS.